



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**30 September 2020**

---

## **Update to Settlement of Institutional Entitlement Offer**

Bionomics Limited (ASX: BNO) (**Bionomics**) refers to its 1 for 12.54 pro rata accelerated non-renounceable entitlement offer, announced on Thursday, 24 September 2020 (**Entitlement Offer** or **Offer**).

As announced on Monday, 28 September 2020, the accelerated institutional component of the Entitlement Offer (**Institutional Entitlement Offer**) raised approximately \$893,235 at the offer price of \$0.04 per new fully paid ordinary share in Bionomics (**New Shares**).

That announcements released by Bionomics in connection with the Entitlement Offer, including the Appendix 3B released on Thursday, 24 September 2020, state that the New Shares to be issued under the Institutional Entitlement Offer are to commence trading on Tuesday, 6 October 2020.

Due to changes to anticipated settlement arrangements, Bionomics advises that the New Shares to be issued under the Institutional Entitlement Offer are now expected to commence trading on Wednesday, 7 October 2020.

Bionomics confirms that there are no other changes to the timetable announced in connection with the Entitlement Offer.

**AUTHORISED BY THE COMPANY SECRETARY**

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
Bionomics Limited  
31 Dalglish St,  
Thebarton, South Australia  
+61 8 8354 6100

### **About Bionomics Limited**

Bionomics Limited (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

**Important information**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which such an offer would be illegal. Neither the entitlements nor the New Shares to be offered and sold in the Entitlement Offer have been, or will be, registered under the U.S. Securities Act of 1933 (U.S. Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the entitlements may not be exercised or taken up by, and the New Shares may not be offered or sold, directly or indirectly, to, persons in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities law of any state or other jurisdiction of the United States.